BioLineRx Ltd. (BLRX) Short Interest Update
BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 384,624 shares, a drop of 52.2% from the August 15th total of 804,376 shares. Based on an average daily trading volume, of 360,841 shares, the short-interest ratio is currently 1.1 days.
Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC raised its position in BioLineRx by 443.4% during the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter valued at $126,000. KCG Holdings Inc. raised its position in BioLineRx by 715.9% during the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC acquired a new position in BioLineRx during the first quarter valued at $3,018,000. 32.27% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on BLRX shares. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “sell” rating in a research note on Tuesday, June 20th. Maxim Group set a $3.00 price target on BioLineRx and gave the stock a “buy” rating in a research note on Monday, July 10th. Oppenheimer Holdings, Inc. started coverage on BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price target on the stock. ValuEngine raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Roth Capital started coverage on BioLineRx in a research note on Thursday, August 3rd. They issued a “buy” rating and a $3.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $2.59.
Shares of BioLineRx (NASDAQ:BLRX) opened at 1.05 on Friday. The firm has a 50-day moving average price of $1.08 and a 200-day moving average price of $0.97. The firm’s market capitalization is $100.40 million. BioLineRx has a 52 week low of $0.80 and a 52 week high of $1.42.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). On average, equities analysts expect that BioLineRx will post ($0.24) earnings per share for the current fiscal year.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.